Thrivent Financial for Lutherans’s Nektar Therapeutics NKTR Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2023
Q2 | – | Sell |
-12,418
| Closed | -$131K | – | 2511 |
|
|
2023
Q1 | $131K | Sell |
12,418
-435
| -3% | -$13.2K | ﹤0.01% | 2405 |
|
|
2022
Q4 | $436K | Sell |
12,853
-62
| -0.5% | -$3K | ﹤0.01% | 2154 |
|
|
2022
Q3 | $620K | Buy |
12,915
+715
| +6% | +$42.5K | ﹤0.01% | 1968 |
|
|
2022
Q2 | $695K | Buy |
12,200
+2,184
| +22% | +$138K | ﹤0.01% | 1920 |
|
|
2022
Q1 | $810K | Buy |
10,016
+3
| +0% | +$444 | ﹤0.01% | 1944 |
|
|
2021
Q4 | $2.03M | Buy |
10,013
+6,810
| +213% | +$1.48M | ﹤0.01% | 1384 |
|
|
2021
Q3 | $863K | Sell |
3,203
-776
| -20% | -$187K | ﹤0.01% | 1915 |
|
|
2021
Q2 | $1.02M | Buy |
3,979
+750
| +23% | +$208K | ﹤0.01% | 1823 |
|
|
2021
Q1 | $969K | Buy |
3,229
+98
| +3% | +$30.5K | ﹤0.01% | 1892 |
|
|
2020
Q4 | $798K | Sell |
3,131
-989
| -24% | -$256K | ﹤0.01% | 1908 |
|
|
2020
Q3 | $1.02M | Sell |
4,120
-4,666
| -53% | -$1.47M | ﹤0.01% | 1548 |
|
|
2020
Q2 | $3.05M | Buy |
8,786
+213
| +2% | +$66.5K | 0.01% | 872 |
|
|
2020
Q1 | $2.29M | Buy |
8,573
+5,509
| +180% | +$1.7M | 0.01% | 895 |
|
|
2019
Q4 | $992K | Buy |
+3,064
| New | +$888K | ﹤0.01% | 1497 |
|
|
2019
Q3 | – | Sell |
-523
| Closed | -$279K | – | 2226 |
|
|
2019
Q2 | $279K | Buy |
523
+5
| +1% | +$2.51K | ﹤0.01% | 2043 |
|
|
2019
Q1 | $261K | Buy |
518
+49
| +10% | +$29K | ﹤0.01% | 2044 |
|
|
2018
Q4 | $231K | Buy |
469
+8
| +2% | +$4.83K | ﹤0.01% | 1903 |
|
|
2018
Q3 | $422K | Buy |
461
+10
| +2% | +$8.54K | ﹤0.01% | 1763 |
|
|
2018
Q2 | $330K | Buy |
451
+3
| +0.7% | +$3.46K | ﹤0.01% | 1859 |
|
|
2018
Q1 | $714K | Sell |
448
-6,062
| -93% | -$7.81M | ﹤0.01% | 1429 |
|
|
2017
Q4 | $5.83M | Buy |
6,510
+128
| +2% | +$75.7K | 0.02% | 600 |
|
|
2017
Q3 | $2.3M | Buy |
6,382
+107
| +2% | +$33.5K | 0.01% | 818 |
|
|
2017
Q2 | $1.84M | Buy |
6,275
+631
| +11% | +$182K | 0.01% | 849 |
|
|
2017
Q1 | $1.99M | Buy |
5,644
+167
| +3% | +$37.5K | 0.01% | 844 |
|
|
2016
Q4 | $1.01M | Buy |
5,477
+785
| +17% | +$160K | ﹤0.01% | 1147 |
|
|
2016
Q3 | $1.21M | Buy |
4,692
+280
| +6% | +$72.1K | 0.01% | 1060 |
|
|
2016
Q2 | $942K | Buy |
4,412
+349
| +9% | +$78K | ﹤0.01% | 1125 |
|
|
2016
Q1 | $838K | Buy |
4,063
+291
| +8% | +$55.9K | ﹤0.01% | 1142 |
|
|
2015
Q4 | $953K | Buy |
3,772
+102
| +3% | +$21K | ﹤0.01% | 1088 |
|
|
2015
Q3 | $603K | Buy |
3,670
+337
| +10% | +$59.6K | ﹤0.01% | 1132 |
|
|
2015
Q2 | $626K | Buy |
+3,333
| New | +$574K | ﹤0.01% | 998 |
|
Other funds holding NKTR
DTC
MAM
SCM
Thrivent Financial for Lutherans's NKTR Position: Q2 2023 in Review
Thrivent Financial for Lutherans sold out of Nektar Therapeutics (NKTR) in Q2 2023, closing a stake of 12,418 shares — an estimated $131K sold.
Thrivent Financial for Lutherans first reported a position in NKTR in Q2 2015 and held it in 31 quarters. The position peaked at $5.83M in Q4 2017. 146 funds tracked by Wall St. Rank hold NKTR as of Q2 2023.
- Thrivent Financial for Lutherans reported no remaining Nektar Therapeutics position as of Q2 2023 after selling out during the quarter.
- Thrivent Financial for Lutherans sold 12,418 Nektar Therapeutics shares in Q2 2023, an estimated $131K.
- Thrivent Financial for Lutherans first reported a position in Nektar Therapeutics in Q2 2015 and held it in 31 quarters.
- Thrivent Financial for Lutherans's Nektar Therapeutics position peaked at $5.83M in Q4 2017.
- 146 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q2 2023.
Based on Thrivent Financial for Lutherans's 13F filing for Q2 2023, filed 14 Aug 2023.